Bristol Myers Squibb Plans Devens, Massachusetts, Cell Therapy Manufacturing Center
The new cell therapy facility will be located on Bristol Myers Squibb’s current 89-acre Devens campus that supports process development, clinical manufacturing and commercial manufacturing for biologics medicines, including an immuno-oncology medicine. The project is part of significant investment to support clinical and commercial manufacturing of transformative cell therapies for patients with aggressive hematological cancers.
“Bristol Myers Squibb is at the forefront of manufacturing innovations, and we are proud that our new cell therapy facility in the Boston area will include many next generation technologies and the latest integrated digital systems,” said Ann Lee, Ph.D., head, Cell Therapy Development & Operations, Bristol Myers Squibb. “Bristol Myers Squibb has designed a reliable manufacturing and global supply chain network comprising internal manufacturing facilities, which include Bothell, Washington, Summit, New Jersey, and Warren, New Jersey, in the U.S., as well as external manufacturing facilities in the U.S., Europe and Japan. Expanding our global footprint is critical to supplying these transformational products to patients around the world.”
The Devens site is the latest investment from Bristol Myers Squibb as the company expands its robust global manufacturing network. The Devens site will be equipped to enable quick ramp up of capacity for clinical and commercial cell therapy products. BMS also operates two R&D facilities in Cambridge, Massachusetts, and will be bringing those two sites together into a new building at Cambridge Crossing in 2023.
Overlook Produce and Farm Adventures Plans Rockingham County, Virginia, Produce Packing Hub
What’s Driving Record Industrial Real Estate Demand
2020 Top States for Doing Business Showcase Their Pro-Business Environments
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Pandemic Fuels Data Center Growth
Trends in Office and Industrial Parks
35th Annual Survey of Corporate Executives Commentary: Change in Site Selection Priorities and Plans Over the Short and Long Term